Cusabio Technology LLC
@cusabio.bsky.social
Cusabio is a biotechnology enterprise specialized in the R&D, production and sales of Elisa kit, protein and antibodies.
HNRNPC Recombinant Monoclonal Antibody
CSB-RA010605A0HU
CSB-RA010605A0HU
December 3, 2025 at 1:38 AM
HNRNPC Recombinant Monoclonal Antibody
CSB-RA010605A0HU
CSB-RA010605A0HU
WORLD AIDS DAY
Targeting Understanding,Advancing Hope
Targeting Understanding,Advancing Hope
December 2, 2025 at 4:02 AM
WORLD AIDS DAY
Targeting Understanding,Advancing Hope
Targeting Understanding,Advancing Hope
🦠 #CD24 is a glycosylphosphatidylinositol (GPI)-anchored protein primarily expressed on immune cells, epithelial cells, and tumor cells. It plays a key role in immune regulation, particularly in dampening excessive immune responses. Read more: bit.ly/3Dc2M1O
CD24: A Key Element in the EXO-CD24 Technique for Combating COVID-19- CUSABIO
EXO-CD24 is a therapeutic technique for Combating COVID-19. If EXO-CD24 proves to be safe and effective, CD24 will largely participate in the COVID-19 therapy. What is CD24 and how might it work in CO...
bit.ly
February 28, 2025 at 1:06 AM
🦠 #CD24 is a glycosylphosphatidylinositol (GPI)-anchored protein primarily expressed on immune cells, epithelial cells, and tumor cells. It plays a key role in immune regulation, particularly in dampening excessive immune responses. Read more: bit.ly/3Dc2M1O
Amgen’s multi-million dollar investment in GPRC5D-targeted CAR-T therapy highlights its potential to reshape MM treatment. As research advances, could GPRC5D be the future of immunotherapy? Read more: bit.ly/42l1Emy
GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM) - Cusabio
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) has emerged as a promising therapeutic target, garnering significant attention in the field of oncology and immunotherapy. Particularly in ...
bit.ly
January 22, 2025 at 8:36 AM
Amgen’s multi-million dollar investment in GPRC5D-targeted CAR-T therapy highlights its potential to reshape MM treatment. As research advances, could GPRC5D be the future of immunotherapy? Read more: bit.ly/42l1Emy
Recently, Sanofi’s $20M investment in ZT-01 for type 1 diabetes and Novartis’s $745M deal for SSTR2 radiotherapeutics both point to one thing: SSTR2 is emerging as a key target in modern drug development.
👉 Read more: bit.ly/4a1Dlw2
👉 Read more: bit.ly/4a1Dlw2
SSTR2: A Prominent Target in SSTR Family, Offers a More Precise Therapy in Neuroendocrine Tumors (NET) - Cusabio
Recently, Sanofi invested $20 million to gain priority negotiation rights for Zucara Therapeutics' novel SSTR2-targeting drug candidate ZT-01 for type 1 diabetes. ZT-01, an SSTR2 receptor antagonist, ...
bit.ly
January 16, 2025 at 1:12 AM
Recently, Sanofi’s $20M investment in ZT-01 for type 1 diabetes and Novartis’s $745M deal for SSTR2 radiotherapeutics both point to one thing: SSTR2 is emerging as a key target in modern drug development.
👉 Read more: bit.ly/4a1Dlw2
👉 Read more: bit.ly/4a1Dlw2
Dr. Lola Zerbib and her team highlight alpelisib, a PI3Kα inhibitor, as a breakthrough for #PIK3CA/TEK-related #VenousMalformations, reducing lesions by 33.4% (PIK3CA) and 27.8% (TEK) in therapy-resistant patients.
Learn more: www.nature.com/articles/s41...
Learn more: www.nature.com/articles/s41...
January 14, 2025 at 1:26 AM
Dr. Lola Zerbib and her team highlight alpelisib, a PI3Kα inhibitor, as a breakthrough for #PIK3CA/TEK-related #VenousMalformations, reducing lesions by 33.4% (PIK3CA) and 27.8% (TEK) in therapy-resistant patients.
Learn more: www.nature.com/articles/s41...
Learn more: www.nature.com/articles/s41...
🎉 As we celebrate CUSABIO’s 17th Anniversary, we invite you to share your story with us!
📅 Submission Deadline: February 15, 2025
🎁 𝟏𝟎𝟎% 𝐖𝐢𝐧 𝐑𝐚𝐭𝐞: Every approved story wins a prize!
👉 Celebrate with us: bit.ly/3Dnp1BH
#CUSABIO17 #Anniversary #Research #ShareYourStory
📅 Submission Deadline: February 15, 2025
🎁 𝟏𝟎𝟎% 𝐖𝐢𝐧 𝐑𝐚𝐭𝐞: Every approved story wins a prize!
👉 Celebrate with us: bit.ly/3Dnp1BH
#CUSABIO17 #Anniversary #Research #ShareYourStory
January 13, 2025 at 6:38 AM
🎉 As we celebrate CUSABIO’s 17th Anniversary, we invite you to share your story with us!
📅 Submission Deadline: February 15, 2025
🎁 𝟏𝟎𝟎% 𝐖𝐢𝐧 𝐑𝐚𝐭𝐞: Every approved story wins a prize!
👉 Celebrate with us: bit.ly/3Dnp1BH
#CUSABIO17 #Anniversary #Research #ShareYourStory
📅 Submission Deadline: February 15, 2025
🎁 𝟏𝟎𝟎% 𝐖𝐢𝐧 𝐑𝐚𝐭𝐞: Every approved story wins a prize!
👉 Celebrate with us: bit.ly/3Dnp1BH
#CUSABIO17 #Anniversary #Research #ShareYourStory
DDR1 plays key roles in cell proliferation, migration & tumor invasion. Recent research highlights its role in forming a barrier that blocks T cells, helping tumors evade immunity. Inhibiting DDR1 could restore immune cell activity, offering exciting potential for cancer treatment. bit.ly/4iUp7Ry
DDR1; Tumor Therapy; TME
DDR1 has been newly identified as a member of the receptor tyrosine kinases (RTKs) family. It is widely recognized that RTKs control cell proliferation and differentiation, which are involved in tumor...
bit.ly
January 6, 2025 at 1:26 AM
DDR1 plays key roles in cell proliferation, migration & tumor invasion. Recent research highlights its role in forming a barrier that blocks T cells, helping tumors evade immunity. Inhibiting DDR1 could restore immune cell activity, offering exciting potential for cancer treatment. bit.ly/4iUp7Ry
𝐇𝐞𝐥𝐥𝐨, 𝐁𝐥𝐮𝐞𝐬𝐤𝐲! 🌟
We’re CUSABIO, trusted by researchers worldwide for 17+ years. Our high-quality proteins, antibodies, and ELISA kits support research in cancer, immunology, neuroscience, and more. 🧪
“𝒀𝒐𝒖𝒓 𝒈𝒐𝒐𝒅 𝒑𝒂𝒓𝒕𝒏𝒆𝒓 𝒊𝒏 𝒃𝒊𝒐𝒍𝒐𝒈𝒚 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉.”
Follow us for updates and collaboration opportunities!
We’re CUSABIO, trusted by researchers worldwide for 17+ years. Our high-quality proteins, antibodies, and ELISA kits support research in cancer, immunology, neuroscience, and more. 🧪
“𝒀𝒐𝒖𝒓 𝒈𝒐𝒐𝒅 𝒑𝒂𝒓𝒕𝒏𝒆𝒓 𝒊𝒏 𝒃𝒊𝒐𝒍𝒐𝒈𝒚 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉.”
Follow us for updates and collaboration opportunities!
January 3, 2025 at 9:31 AM
𝐇𝐞𝐥𝐥𝐨, 𝐁𝐥𝐮𝐞𝐬𝐤𝐲! 🌟
We’re CUSABIO, trusted by researchers worldwide for 17+ years. Our high-quality proteins, antibodies, and ELISA kits support research in cancer, immunology, neuroscience, and more. 🧪
“𝒀𝒐𝒖𝒓 𝒈𝒐𝒐𝒅 𝒑𝒂𝒓𝒕𝒏𝒆𝒓 𝒊𝒏 𝒃𝒊𝒐𝒍𝒐𝒈𝒚 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉.”
Follow us for updates and collaboration opportunities!
We’re CUSABIO, trusted by researchers worldwide for 17+ years. Our high-quality proteins, antibodies, and ELISA kits support research in cancer, immunology, neuroscience, and more. 🧪
“𝒀𝒐𝒖𝒓 𝒈𝒐𝒐𝒅 𝒑𝒂𝒓𝒕𝒏𝒆𝒓 𝒊𝒏 𝒃𝒊𝒐𝒍𝒐𝒈𝒚 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉.”
Follow us for updates and collaboration opportunities!